Christina W. Yde

1.7k total citations
59 papers, 1.2k citations indexed

About

Christina W. Yde is a scholar working on Oncology, Cancer Research and Molecular Biology. According to data from OpenAlex, Christina W. Yde has authored 59 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Oncology, 21 papers in Cancer Research and 20 papers in Molecular Biology. Recurrent topics in Christina W. Yde's work include Cancer Genomics and Diagnostics (19 papers), Estrogen and related hormone effects (9 papers) and Cancer-related Molecular Pathways (8 papers). Christina W. Yde is often cited by papers focused on Cancer Genomics and Diagnostics (19 papers), Estrogen and related hormone effects (9 papers) and Cancer-related Molecular Pathways (8 papers). Christina W. Yde collaborates with scholars based in Denmark, Germany and Sweden. Christina W. Yde's co-authors include Anne E. Lykkesfeldt, Olaf‐Georg Issinger, Bárbara Guerra, Finn Cilius Nielsen, Karsten Niefind, ASTRID M. PEDERSEN, Susan Thrane, Ulrik Lassen, Anne‐Vibeke Lænkholm and Lise Barlebo Ahlborn and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Journal of Molecular Biology.

In The Last Decade

Christina W. Yde

53 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Christina W. Yde Denmark 22 655 458 323 223 188 59 1.2k
Samuel Seoane Spain 18 492 0.8× 361 0.8× 183 0.6× 121 0.5× 91 0.5× 38 1.1k
Wanleng Deng United States 14 907 1.4× 659 1.4× 236 0.7× 186 0.8× 272 1.4× 20 1.4k
Teeru Bihani United States 14 530 0.8× 388 0.8× 210 0.7× 305 1.4× 353 1.9× 27 1.1k
Ariella B. Hanker United States 15 942 1.4× 759 1.7× 453 1.4× 157 0.7× 445 2.4× 41 1.6k
Ashish Juvekar United States 11 804 1.2× 468 1.0× 316 1.0× 92 0.4× 131 0.7× 22 1.3k
William Senapedis United States 29 1.6k 2.5× 661 1.4× 202 0.6× 128 0.6× 193 1.0× 79 2.1k
Carolyn Sidor United States 20 871 1.3× 553 1.2× 433 1.3× 280 1.3× 147 0.8× 42 1.6k
Josh Lauring United States 22 1.4k 2.1× 515 1.1× 510 1.6× 194 0.9× 272 1.4× 42 2.0k
Doris R. Siwak United States 18 1.2k 1.8× 462 1.0× 224 0.7× 71 0.3× 213 1.1× 27 1.7k
Katharine Ellwood‐Yen United States 8 787 1.2× 336 0.7× 287 0.9× 135 0.6× 531 2.8× 10 1.3k

Countries citing papers authored by Christina W. Yde

Since Specialization
Citations

This map shows the geographic impact of Christina W. Yde's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christina W. Yde with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christina W. Yde more than expected).

Fields of papers citing papers by Christina W. Yde

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christina W. Yde. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christina W. Yde. The network helps show where Christina W. Yde may publish in the future.

Co-authorship network of co-authors of Christina W. Yde

This figure shows the co-authorship network connecting the top 25 collaborators of Christina W. Yde. A scholar is included among the top collaborators of Christina W. Yde based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christina W. Yde. Christina W. Yde is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Yde, Christina W., A. Schmidt, Martin Højgaard, et al.. (2026). Immune Cell Modulation of Patient-Matched Organoid Drug Response in Precision Cancer Medicine Platform. Cells. 15(3). 259–259.
2.
Spanggaard, Iben, Lise Barlebo Ahlborn, Kristoffer Staal Rohrberg, et al.. (2025). Mutational Landscape Assessed in Tumor Tissue and Circulating Tumor DNA During Treatment of Patients with HER2/ERBB2-Mutated Solid Tumors. BMC Cancer. 25(1). 1272–1272.
3.
Draghi, Arianna, Annie Borch, Filip Mundt, et al.. (2024). Nivolumab Reaches Brain Lesions in Patients with Recurrent Glioblastoma and Induces T-cell Activity and Upregulation of Checkpoint Pathways. Cancer Immunology Research. 12(9). 1202–1220. 6 indexed citations
4.
Debnath, Olivia, Naveed Ishaque, Jane Skjøth‐Rasmussen, et al.. (2024). Immunotherapy drives mesenchymal tumor cell state shift and TME immune response in glioblastoma patients. Neuro-Oncology. 26(8). 1453–1466. 7 indexed citations
5.
Draghi, Arianna, Joachim Stoltenborg Granhøj, Christina W. Yde, et al.. (2023). Final results: Dose escalation study of a personalized peptide-based neoantigen vaccine in patients with metastatic melanoma.. Journal of Clinical Oncology. 41(16_suppl). 9551–9551. 3 indexed citations
6.
Bertelsen, Birgitte, Karin Wadt, Iben Spanggaard, et al.. (2023). New pathogenic germline variants identified in mesothelioma. Lung Cancer. 179. 107172–107172. 3 indexed citations
7.
Borch, Annie, Anne-Mette Bjerregaard, Oľga Østrup, et al.. (2023). Neoepitope load, T cell signatures and PD-L2 as combined biomarker strategy for response to checkpoint inhibition immunotherapy. Frontiers in Genetics. 14. 1058605–1058605.
8.
Nielsen, Morten, Zsófia Sztupinszki, Arianna Draghi, et al.. (2022). Coexisting Alterations of MHC Class I Antigen Presentation and IFNγ Signaling Mediate Acquired Resistance of Melanoma to Post–PD-1 Immunotherapy. Cancer Immunology Research. 10(10). 1254–1262. 9 indexed citations
9.
Bol, Kalijn F., Arianna Draghi, Nana Haahr Overgaard, et al.. (2022). Personalized therapy with peptide-based neoantigen vaccine (EVX-01) including a novel adjuvant, CAF®09b, in patients with metastatic melanoma. Technical University of Denmark, DTU Orbit (Technical University of Denmark, DTU). 38 indexed citations
10.
Brieghel, Christian, Michael Asger Andersen, Christina W. Yde, et al.. (2021). Clinical Outcomes in Patients with Multi-Hit TP53 Chronic Lymphocytic Leukemia Treated with Ibrutinib. Clinical Cancer Research. 27(16). 4531–4538. 24 indexed citations
11.
Kverneland, Anders, Christopher A. Chamberlain, Troels Holz Borch, et al.. (2021). Adoptive cell therapy with tumor-infiltrating lymphocytes supported by checkpoint inhibition across multiple solid cancer types. Journal for ImmunoTherapy of Cancer. 9(10). e003499–e003499. 45 indexed citations
12.
Yde, Christina W., Oľga Østrup, Finn Cilius Nielsen, et al.. (2021). Tumor mutational burden and purity adjustment before and after treatment with temozolomide in 27 paired samples of glioblastoma: a prospective study. Molecular Oncology. 16(1). 206–218. 6 indexed citations
13.
Rohrberg, Kristoffer Staal, Lise Barlebo Ahlborn, Ane Yde Schmidt, et al.. (2018). Copenhagen Prospective Personalized Oncology (CoPPO)—Clinical Utility of Using Molecular Profiling to Select Patients to Phase I Trials. Clinical Cancer Research. 25(4). 1239–1247. 59 indexed citations
14.
Hansen, Thomas van Overeem, et al.. (2017). Genetic Characterization of Adenoid Cystic Carcinoma of the Minor Salivary Glands: A Potential Familial Occurrence in First-Degree Relatives. Head and Neck Pathology. 11(4). 546–551. 5 indexed citations
15.
Yde, Christina W., et al.. (2016). Copenhagen prospective personalized oncology (CoPPO): Genomic profiling to select patients for phase 1 trials. Annals of Oncology. 27. vi545–vi545. 1 indexed citations
16.
PEDERSEN, ASTRID M., et al.. (2015). Aurora kinase A and B as new treatment targets in aromatase inhibitor-resistant breast cancer cells. Breast Cancer Research and Treatment. 149(3). 715–726. 38 indexed citations
17.
Kirkegaard, Tove, Christina W. Yde, Marie Kveiborg, & Anne E. Lykkesfeldt. (2014). The broad-spectrum metalloproteinase inhibitor BB-94 inhibits growth, HER3 and Erk activation in fulvestrant-resistant breast cancer cell lines. International Journal of Oncology. 45(1). 393–400. 8 indexed citations
18.
19.
Thrane, Susan, Anne E. Lykkesfeldt, Mathilde Skaarup Larsen, Boe Sandahl Sørensen, & Christina W. Yde. (2013). Estrogen receptor α is the major driving factor for growth in tamoxifen-resistant breast cancer and supported by HER/ERK signaling. Breast Cancer Research and Treatment. 139(1). 71–80. 61 indexed citations
20.
Yde, Christina W., Mathias P. Clausen, Martin V. Bennetzen, et al.. (2009). The antipsychotic drug chlorpromazine enhances the cytotoxic effect of tamoxifen in tamoxifen-sensitive and tamoxifen-resistant human breast cancer cells. Anti-Cancer Drugs. 20(8). 723–735. 60 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Samuel Seoane Breakdown of academic impact, for papers by Wanleng Deng Breakdown of academic impact, for papers by Teeru Bihani Breakdown of academic impact, for papers by Ariella B. Hanker Breakdown of academic impact, for papers by Ashish Juvekar Breakdown of academic impact, for papers by William Senapedis Breakdown of academic impact, for papers by Carolyn Sidor Breakdown of academic impact, for papers by Josh Lauring Breakdown of academic impact, for papers by Doris R. Siwak Breakdown of academic impact, for papers by Katharine Ellwood‐Yen
Rankless by CCL
2026